CLClinicLens

Oncology

Population Pharmacokinetics and Exposure-Response Analyses of Vepdegestrant, a First-in-Class PROteolysis-TArgeting Chimera Estrogen Receptor Degrader. | Clinic

Population pharmacokinetic (PK) and exposure-response analyses were performed to characterize the PK and exposure-response relationships of vepdegestrant, a first-in-class, oral PROteolysis-TArgeting Chimera estrogen receptor degrader. Population PK and exposure-response analyses

Medical Literature · Updated

← Back to articles
This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.